Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Sacituzumab Govitecan-hziy|DRUG: Eribulin Mesylate Injection|DRUG: Capecitabine Oral Product|DRUG: Gemcitabine Injection|DRUG: Vinorelbine injection
Sponsor: Gilead Sciences